Biosimilars and interchangeable biologic
โ Niazi, Sarfaraz
๐ Library
๐
2016
๐ CRC Press
๐ English
โฆ LIBER โฆ
๐
Biosimilars and interchangeable biologics. Tactical elements
โ Scribed by Niazi, Sarfaraz
- Publisher
- CRC Press
- Year
- 2016
- Tongue
- English
- Leaves
- 612
- Category
- Library
โฌ Acquire This Volume
No coin nor oath required. For personal study only.
โฆ Table of Contents
Content: Structural and functional considerations --
Immunogenicity considerations --
Product development strategies --
Stability and formulation considerations --
Establishing biosimilarity --
Recombinant expression systems --
Upstream systems optimization --
Downstream system optimization --
Single use manufacturing systems (SUMS) --
Commercial manufacturing systems --
Outsourcing considerations.
โฆ Subjects
Pharmaceutical biotechnology. Biopharmaceutics. Pharmaceutical industry -- Technological innovations. Biologicals. Biosimilar Pharmaceuticals -- standards. Drug Approval. Drug Discovery -- standards. Drug Evaluation -- standards. Drug Industry -- standards. MEDICAL / Pharmacology
๐ SIMILAR VOLUMES
Biosimilar and Interchangeable Biologics
โ Sarfaraz K. Niazi
๐ Library
๐
2015
๐ CRC Press
๐ English
Biosimilars and interchangeable biologic
โ Niazi, Sarfaraz
๐ Library
๐
2016
๐ CRC Press
๐ English
Nonclinical Development of Novel Biologi
โ Lisa M. Plitnick and Danuta J. Herzyk (Eds.)
๐ Library
๐
2013
Biosimilars : design and analysis of fol
โ Shein-Chung Chow
๐ Library
๐
2014
๐ Taylor & Francis
๐ English
"This is the first book entirely devoted to the design and analysis for assessment of biosimilarity and drug interchangeability of biosimilars, and test for comparability in manufacturing processes of biologic products. It covers all of the statistical issues that may occur in biosimilar studies u
Biosimilars: Design and Analysis of Foll
โ Shein-Chung Chow (Author)
๐ Library
๐
2013
๐ Chapman and Hall/CRC
<p>As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator`s biologic products. But scientific chal